Q-omics provides the consensus-scored SYNJ1 profile across patient tissues and cancer cell-line models. SYNJ1 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, SYNJ1 is differentially expressed in 9, with the highest sampling consensus in THCA. Additionally, SYNJ1 protein abundance shows 33,636 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight HNSC, THCA, and GBM as cancer lineages where SYNJ1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SYNJ1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SYNJ1 survival associations across molecular data types. SYNJ1 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (3) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SYNJ1 RNA expression–survival associations across cancer types. High SYNJ1 expression shows unfavorable associations in ACC, MESO and BLCA, but favorable associations in HNSC, KIRC and PAAD. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for SYNJ1 RNA expression.
This table summarizes SYNJ1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 6. The strongest signals are observed in THCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for SYNJ1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SYNJ1 shows lower tumor expression in THCA, KICH, COAD, LUSC and LUAD and higher tumor expression in LIHC. The THCA box plot shows higher SYNJ1 RNA expression in normal versus tumor tissue (log2 FC = −0.750, t-test p < 0.001).
This table shows molecular features associated with SYNJ1 in patient tissues and cancer cell lines. In patient samples, SYNJ1 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, SYNJ1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BREAST and BLOOD_Leukemia.
